New Findings from National Cheng Kung University in the Area of Health Insurance Reported (10-year trends in statin utilization in Taiwan: a…

New Findings from National Cheng Kung University in the Area of Health Insurance Reported (10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database)

By a News Reporter-Staff News Editor at Insurance Weekly News -- Current study results on Health Insurance have been published. According to news reporting originating from Tainan, Taiwan, by VerticalNews correspondents, research stated, "Statins have been commonly used to treat patients with hypercholesterolaemia and to prevent cardiovascular disease (CVD) worldwide. This study examined trends in use of statins in Taiwan from 2002 to 2011."

Our news editors obtained a quote from the research from National Cheng Kung University, "This is a retrospective observational study focusing on the utilisation of statins. The monthly claims data for statins between 2002 and 2011 were retrieved from Taiwan's National Health Insurance Research Database. We calculated the yearly prescription rate per new user for each statin. Products were classified as high-intensity/moderate-intensity/low-intensity statins by type of statin and dosage. Users were also classified based on disease histories. The number of statin users increased from 10 299 (~1.4% of adults) in 2002 to 50 687 (~6.3% of adults) in 2011. Atorvastatin was the most commonly used agent (28.4%-36.7%) during the study period. After 2007, simvastatin ranked second with 21.7% market share, followed by rosuvastatin, a newer agent that exhibited a substantial growth in prescription rates (3.4% in 2005 and 19.5% in 2011). In 2011, 94.0% of new statin users used statin monotherapies, and 6.0% used combination therapies. Use of moderate-intensity statins increased from 49.0% in 2002 to 71.0% in 2011, while high-intensity statins remained low. Patients with history of coronary events or cerebrovascular events were more likely to be prescribed higher intensity statins compared with those without. Prescribing of higher intensity statins was not greater among people with diabetes compared with those without during 2007-2011. Selection of statins did not differ between people with versus without history of myopathy or liver injury. Atorvastatin was the most commonly used statin in Taiwan during 2002-2011."

According to the news editors, the research concluded: "While patients with history of CVD were more likely to be prescribed higher intensity statins compared with those without, this difference was not found comparing those with and without diabetes."

For more information on this research see: 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database. Bmj Open, 2017;7(5):e014150. (BMJ Publishing Group - group.bmj.com/; Bmj Open - bmjopen.bmj.com/)

The news editors report that additional information may be obtained by contacting H.C. Hsieh, School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Additional authors for this research include J.C. Hsu and C.Y Lu.

Keywords for this news article include: Asia, Tainan, Taiwan, Angiology, Atorvastatin, Health Insurance, Insurance Companies, Cardiovascular Diseases and Conditions.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC